Home > Oncology > ASCO GU 2022 > Prostate Cancer > First-line treatment with olaparib significantly improves PFS in mCRPC

First-line treatment with olaparib significantly improves PFS in mCRPC

Presented By
Dr Fred Saad, Centre Hospitalier de l’Université de Montréal, Canada

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GU 2022
Trial
Phase 3, PROpel
The primary analysis of the PROpel trial showed that the addition of olaparib to abiraterone in first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) significantly improved radiographic progression-free survival (rPFS). Patients with mCRPC treated in the first-line setting have a median survival of approximately 3 years in clinical trials. However, in clinical practice, approximately half of these patients receive only 1 line of active therapy, achieving a median survival of less than 2 years [1]. Recently, olaparib monotherapy has demonstrated to improve survival in patients with mCRPC with homologous recombination repair (HRR) gene alterations, post-next-generation hormonal agents [2,3]. In addition, the combination of olaparib plus abiraterone following docetaxel has shown to prolong rPFS irrespective of HRR mutational status [4]. The phase 3 PROpel study (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on